Scientific Director of the National Research Center for Epidemiology and Microbiology (NRCEM) named after N. F. Gamaleya, Alexander Gintsburg, announced the success of scientists in developing an experimental vaccine for the treatment of melanoma. Studies conducted on animals have shown high efficacy of the new drug.
According to Gintsburg, the efficacy of the vaccine reaches 90%, and in the case of complete tumor disappearance, this figure is 100%. At the same time, the data on metastases are also impressive — about 90% efficacy. This creates significant hopes for successful treatment of melanoma in humans.
The first clinical trials on patients are scheduled for the beginning of 2026. This drug, named "NEOONKOVAK", has received permission from the Ministry of Health for use in clinical practice.
The new vaccine promises to change the approach to melanoma therapy and provide patients with new opportunities to fight this dangerous disease. Researchers are confident that "NEOONKOVAK" will open new horizons in the treatment of oncology, improving the prognosis for many people.
Read more materials on the topic:
- New cancer vaccine being tested in Russia
- Gintsburg spoke about how the new cancer vaccine was tested
- Biocomposite for combating melanoma created in Russia
